$OVID
Ovid Therapeutics Inc Stock $ovid

$ovid Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000162828024009809 Filed on March 08, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$148.0K	$141.6K	$391.7K
YoY Change	123.7%	205.88%	-73.93%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.168M	$7.688M	$31.09M
YoY Change	-14.09%	15.38%	-4.15%
% of Gross Profit
Research & Development	$10.40M	$10.64M	$28.59M
YoY Change	57.18%	91.53%	16.12%
% of Gross Profit
Depreciation & Amortization	$136.0K	$140.5K	$568.3K
YoY Change	-5.98%	-24.04%	10.88%
% of Gross Profit
Operating Expenses	$17.57M	$18.33M	$59.67M
YoY Change	17.43%	50.01%	4.6%
Operating Profit	-$17.42M		-$59.28M
YoY Change	16.95%		6.72%
Interest Expense	$5.723M	$2.866M	$6.943M
YoY Change	403.74%	168.35%	269.45%
% of Operating Profit
Other Income/Expense, Net	$5.723M		$6.943M
YoY Change	272.57%		403.4%
Pretax Income	-$11.69M	-$15.32M	-$52.34M
YoY Change	-12.45%	33.18%	-3.38%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$11.69M	-$15.32M	-$52.34M
YoY Change	-12.45%	33.18%	-3.38%
Net Earnings / Revenue	-7901.35%	-10823.7%	-13362.17%
Basic Earnings Per Share	-$0.17		-$0.74
Diluted Earnings Per Share	-$0.17	-$0.22	-$0.74
COMMON SHARES
Basic Shares Outstanding	70.71M shares	70.68M shares	70.58M shares
Diluted Shares Outstanding	70.72M shares		70.58M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$90.26M	$105.8M	$105.8M
YoY Change	-23.33%	-17.96%	-17.96%
Cash & Equivalents	$30.77M	$27.04M	$24.34M
Short-Term Investments	$59.49M	$78.79M	$78.79M
Other Short-Term Assets	$2.911M	$3.764M	$3.764M
YoY Change	61.78%	58.21%	58.21%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$93.17M	$109.6M	$109.6M
YoY Change	-22.05%	-16.58%	-16.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$686.0K	$768.8K	$14.66M
YoY Change	-34.86%	-33.03%	-8.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$22.02M	$17.63M	$17.63M
YoY Change	268.11%	245.6%	213.48%
Other Assets	$174.0K	$209.6K	$1.957M
YoY Change	-18.12%	-19.76%	-0.63%
Total Long-Term Assets	$38.44M	$34.43M	$34.43M
YoY Change	61.2%	44.14%	44.14%
TOTAL ASSETS
Total Short-Term Assets	$93.17M	$109.6M	$109.6M
Total Long-Term Assets	$38.44M	$34.43M	$34.43M
Total Assets	$131.6M	$144.0M	$144.0M
YoY Change	-8.2%	-7.24%	-7.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.596M	$3.703M	$3.703M
YoY Change	96.34%	89.61%	89.61%
Accrued Expenses	$4.039M	$6.525M	$7.771M
YoY Change	-1.14%	44.85%	54.24%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.903M	$11.47M	$11.47M
YoY Change	32.47%	64.12%	64.12%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$44.43M	$44.76M	$44.76M
YoY Change	183.03%	179.69%	179.69%
Total Long-Term Liabilities	$44.43M	$44.76M	$44.76M
YoY Change	183.03%	179.69%	179.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.903M	$11.47M	$11.47M
Total Long-Term Liabilities	$44.43M	$44.76M	$44.76M
Total Liabilities	$53.33M	$56.23M	$56.23M
YoY Change	137.89%	144.55%	144.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$289.6M	-$277.9M
YoY Change	21.22%	23.24%
Common Stock	$71.00K	$70.69K
YoY Change	0.72%	0.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$78.28M	$87.80M	$87.80M
YoY Change
Total Liabilities & Shareholders Equity	$131.6M	$144.0M	$144.0M
YoY Change	-8.2%	-7.24%	-7.24%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$11.69M	-$15.32M	-$52.34M
YoY Change	-12.45%	33.18%	-3.38%
Depreciation, Depletion And Amortization	$136.0K	$140.5K	$568.3K
YoY Change	-5.98%	-24.04%	10.88%
Cash From Operating Activities	-$16.70M	-$11.91M	-$45.80M
YoY Change	38.02%	29.82%	-17.03%
INVESTING ACTIVITIES
Capital Expenditures	$19.00K	$1.220K	$40.31K
YoY Change	40.12%	-98.06%	-96.71%
Acquisitions
YoY Change
Other Investing Activities	$20.21M	-$48.51M	-$2.443M
YoY Change	-33.18%	1081.42%	-97.17%
Cash From Investing Activities	$20.19M	-$48.52M	-$2.581M
YoY Change	-33.22%	1063.59%	-97.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$228.0K	30.03M	$30.54M
YoY Change	240.33%	-68983.92%	16802.21%
NET CHANGE
Cash From Operating Activities	-$16.70M	-11.91M	-$45.80M
Cash From Investing Activities	$20.19M	-48.52M	-$2.581M
Cash From Financing Activities	$228.0K	30.03M	$30.54M
Net Change In Cash	$3.716M	-30.40M	-$17.85M
YoY Change	-79.58%	127.02%	-87.51%
FREE CASH FLOW
Cash From Operating Activities	-$16.70M	-$11.91M	-$45.80M
Capital Expenditures	$19.00K	$1.220K	$40.31K
Free Cash Flow	-$16.72M	-$11.91M	-$45.84M
YoY Change	38.02%	28.95%	-18.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-54169029	usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001636651
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38085
CY2023	dei	Entity Registrant Name EntityRegistrantName	Ovid Therapeutics Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5270895
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	441 Ninth Avenue
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	14th Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10001
CY2023	dei	City Area Code CityAreaCode	646
CY2023	dei	Local Phone Number LocalPhoneNumber	661-7661
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	OVID
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	191100000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	70709857	shares
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	185
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	New York, New York
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27041517	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44867846	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	78791858	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	84133565	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3764332	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2379280	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	109597707	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	131380691	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	17625620	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	5622547	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	1930753	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	1930753	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13894376	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14922669	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	768753	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1147963	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	209574	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	261191	usd
CY2023Q4	us-gaap	Assets Assets	144026783	usd
CY2022Q4	us-gaap	Assets Assets	155265814	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3702936	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1952910	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6525235	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4504669	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1246119	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	533946	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11474290	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6991525	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14755606	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16001725	usd
CY2023Q4	ovid	Royalty Monetization Liability Non Current RoyaltyMonetizationLiabilityNonCurrent	30000000	usd
CY2022Q4	ovid	Royalty Monetization Liability Non Current RoyaltyMonetizationLiabilityNonCurrent	0	usd
CY2023Q4	us-gaap	Liabilities Liabilities	56229896	usd
CY2022Q4	us-gaap	Liabilities Liabilities	22993250	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	ovid	Preferred Stock Share Designated PreferredStockShareDesignated	10000	shares
CY2022Q4	ovid	Preferred Stock Share Designated PreferredStockShareDesignated	10000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1250	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1250	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1250	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1250	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	1	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70691992	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70691992	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70466885	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70466885	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	70692	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	70467	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	365590993	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	357770825	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	702	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-42187	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-277865501	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-225526542	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	87796887	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	132272564	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	144026783	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	155265814	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	391695	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1502748	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	391695	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1502748	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28587884	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24618399	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31085274	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	32432510	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	59673158	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	57050909	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-55548161	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-52338959	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-52338959	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-54169029	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.77
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.77
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70580604	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70424819	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70580604	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70424819	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-52338959	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-54169029	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	702	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-42187	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-52338257	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54211216	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	132272564	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	535201	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7285192	usd
CY2023	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	42889	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-52338959	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	87796887	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	179746436	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	180658	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6556686	usd
CY2022	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-42187	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-54169029	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	132272564	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-52338959	usd
CY2023	ovid	Noncash Consideration Received In Licensing Agreement Transaction NoncashConsiderationReceivedInLicensingAgreementTransaction	0	usd
CY2022	ovid	Noncash Consideration Received In Licensing Agreement Transaction NoncashConsiderationReceivedInLicensingAgreementTransaction	945366	usd
CY2023	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	2003073	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-454811	usd
CY2023	ovid	Change In Accrued Interest And Accretion Of Discounts Short Term Investments ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments	-2172254	usd
CY2022	ovid	Change In Accrued Interest And Accretion Of Discounts Short Term Investments ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments	-1211311	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	7285192	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	6556686	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	568282	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	512505	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1028293	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	869100	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-533946	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	936927	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1385052	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-109292	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1750026	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-5174136	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2020566	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3166606	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45780925	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55227127	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	112443150	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	172964441	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	120000000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	90000000	usd
CY2023	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	10000000	usd
CY2022	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	2500000	usd
CY2023	ovid	Payments For Proceeds From Issuance Of Short Term Note Receivable PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable	0	usd
CY2022	ovid	Payments For Proceeds From Issuance Of Short Term Note Receivable PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable	1000000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	40308	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1224379	usd
CY2023	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	97147	usd
CY2022	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	194397	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2580605	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-87883217	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	535201	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	180658	usd
CY2023	ovid	Proceeds From Royalties Received Financing Activities ProceedsFromRoyaltiesReceivedFinancingActivities	30000000	usd
CY2022	ovid	Proceeds From Royalties Received Financing Activities ProceedsFromRoyaltiesReceivedFinancingActivities	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30535201	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	180658	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-17826329	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-142929686	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46798599	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	189728285	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28972270	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46798599	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	15791769	usd
CY2023	ovid	Conversion Of Short Term Note Receivable To Long Term Equity Investment ConversionOfShortTermNoteReceivableToLongTermEquityInvestment	0	usd
CY2022	ovid	Conversion Of Short Term Note Receivable To Long Term Equity Investment ConversionOfShortTermNoteReceivableToLongTermEquityInvestment	1000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	105800000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	222800000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-277900000	usd
CY2023Q4	ovid	Working Capital WorkingCapital	98100000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45800000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-52300000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates<div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates.</span></div>
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	1200000	usd
CY2022	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0	usd
CY2023	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0	usd
CY2023Q4	ovid	Royalty Monetization Liability Non Current RoyaltyMonetizationLiabilityNonCurrent	30000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P3Y
CY2023	ovid	Defined Contribution Plan Name DefinedContributionPlanName	401(k)-retirement plan
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	311640	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	339405	usd
CY2023Q4	us-gaap	Cash Cash	2701396	usd
CY2023Q4	us-gaap	Cash Cash	2701396	usd
CY2023Q4	ovid	Cash Equivalents Amortized Cost CashEquivalentsAmortizedCost	24340121	usd
CY2023Q4	ovid	Cash Equivalents Unrealized Holding Gains CashEquivalentsUnrealizedHoldingGains	0	usd
CY2023Q4	ovid	Cash Equivalents Unrealized Holding Losses CashEquivalentsUnrealizedHoldingLosses	0	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	24340121	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	78791156	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	702	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	78791858	usd
CY2023Q4	ovid	Cash Cash Equivalents And Available For Sale Debt Securities Amortized Cost CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost	105832673	usd
CY2023Q4	ovid	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Including Cash Equivalents Accumulated Unrealized Holding Gain DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain	702	usd
CY2023Q4	ovid	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Including Cash Equivalents Accumulated Unrealized Holding Loss DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss	0	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	105833375	usd
CY2022Q4	us-gaap	Cash Cash	2853042	usd
CY2022Q4	us-gaap	Cash Cash	2853042	usd
CY2022Q4	ovid	Cash Equivalents Amortized Cost CashEquivalentsAmortizedCost	42014804	usd
CY2022Q4	ovid	Cash Equivalents Unrealized Holding Gains CashEquivalentsUnrealizedHoldingGains	0	usd
CY2022Q4	ovid	Cash Equivalents Unrealized Holding Losses CashEquivalentsUnrealizedHoldingLosses	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	42014804	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	84175752	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	42187	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	84133565	usd
CY2022Q4	ovid	Cash Cash Equivalents And Available For Sale Debt Securities Amortized Cost CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost	129043598	usd
CY2022Q4	ovid	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Including Cash Equivalents Accumulated Unrealized Holding Gain DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain	0	usd
CY2022Q4	ovid	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Including Cash Equivalents Accumulated Unrealized Holding Loss DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss	42187	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	129001411	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0	investment
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0	investment
CY2022	ovid	Available For Sale Securities Gross Realized Gain Loss Net1 AvailableForSaleSecuritiesGrossRealizedGainLossNet1	0	usd
CY2023	ovid	Available For Sale Securities Gross Realized Gain Loss Net1 AvailableForSaleSecuritiesGrossRealizedGainLossNet1	0	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1000899	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	581381	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	768753	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1147963	usd
CY2023	us-gaap	Depreciation Depreciation	419518	usd
CY2022	us-gaap	Depreciation Depreciation	319173	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	182974	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	222100	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	148764	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	193333	usd
CY2022Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P10Y
CY2022Q1	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	19000	sqft
CY2023	us-gaap	Payments For Rent PaymentsForRent	2300000	usd
CY2022Q1	ovid	Lessee Operating Lease Rent Payments Commencement Following This Period LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod	P10M
CY2022Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P10Y
CY2022Q1	ovid	Lessee Operating Lease Free Rent Period LesseeOperatingLeaseFreeRentPeriod	P2M
CY2023Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P9Y
CY2023Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2023Q4	ovid	Lease Incremental Borrowing Rate LeaseIncrementalBorrowingRate	0.0702
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13894376	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14922669	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1246119	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	533946	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14755606	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16001725	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	2167233	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1806028	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2316303	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2316303	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2316303	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2316303	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2469447	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	9877788	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	21612447	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4277034	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3233802	usd
CY2023Q4	ovid	Accrued Research And Development AccruedResearchAndDevelopment	1395751	usd
CY2022Q4	ovid	Accrued Research And Development AccruedResearchAndDevelopment	395247	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	521942	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	682664	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	330508	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	192956	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6525235	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4504669	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2389890	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023	ovid	Common Stock Number Of Votes For Each Share CommonStockNumberOfVotesForEachShare	1	vote
CY2023	us-gaap	Dividends Dividends	0	usd
CY2023	us-gaap	Dividends Dividends	0	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7285192	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6556686	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7285192	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6556686	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10776758	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.97
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y25D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	6188200	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	5.98
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y7M17D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1531907	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4575641	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.89
CY2022	ovid	Share Based Compensation By Share Based Payment Award Options Granted Contractual Life ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife	P9Y3M3D
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	25518	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.91
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	2365643	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	5.56
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12961238	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.13
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y5M1D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	62158	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	6742890	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	5.05
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y2M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	61214	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3038000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.63
CY2023	ovid	Share Based Compensation By Share Based Payment Award Options Granted Contractual Life ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife	P9Y2M12D
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	146346	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.76
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	728346	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	3.44
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15124546	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.87
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5212586	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	9649094	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	4.47
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y11M19D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	2464620	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	9400000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y2M23D
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	12100000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M3D
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	18900000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	10400000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	55653286	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	55472573	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	7522067	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	6332176	usd
CY2023Q4	ovid	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	10909248	usd
CY2022Q4	ovid	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	4246071	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7248199	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4384751	usd
CY2023Q4	ovid	Deferred Tax Assets Royalty Monetization Liability DeferredTaxAssetsRoyaltyMonetizationLiability	8427970	usd
CY2022Q4	ovid	Deferred Tax Assets Royalty Monetization Liability DeferredTaxAssetsRoyaltyMonetizationLiability	0	usd
CY2023Q4	ovid	Deferred Tax Assets Tax Deferred Expense Lease Liability DeferredTaxAssetsTaxDeferredExpenseLeaseLiability	4495402	usd
CY2022Q4	ovid	Deferred Tax Assets Tax Deferred Expense Lease Liability DeferredTaxAssetsTaxDeferredExpenseLeaseLiability	3544624	usd
CY2023Q4	ovid	Deferred Tax Assets Deferred Expense Research And Development Tax Credits DeferredTaxAssetsDeferredExpenseResearchAndDevelopmentTaxCredits	2877649	usd
CY2022Q4	ovid	Deferred Tax Assets Deferred Expense Research And Development Tax Credits DeferredTaxAssetsDeferredExpenseResearchAndDevelopmentTaxCredits	3046253	usd
CY2023Q4	ovid	Deferred Tax Liabilities Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxLiabilitiesTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	0	usd
CY2022Q4	ovid	Deferred Tax Liabilities Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxLiabilitiesTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	0	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	166075	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	241096	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	3903379	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	3198857	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	-434957	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	97494	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	92629410	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	73683989	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	92629410	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	73683989	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0912
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0027
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0132
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0126
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2923
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1850
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0105
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0128
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0062
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0225
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2021Q4	ovid	License Agreement Milestone Payments LicenseAgreementMilestonePayments	203000000	usd
CY2022Q3	ovid	Collaboration And Option Agreement Research Plan And Budget Expected Costs CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts	3000000	usd
CY2023Q2	ovid	Collaboration And Option Agreement Research Plan And Budget Expected Costs CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts	3500000	usd
CY2023	ovid	Contingencies Severance Payments And Benefits Eligibility Following Termination Period ContingenciesSeverancePaymentsAndBenefitsEligibilityFollowingTerminationPeriod	P2Y
CY2023	us-gaap	Equity Securities Fv Ni Unrealized Loss EquitySecuritiesFvNiUnrealizedLoss	800000	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Loss EquitySecuritiesFvNiUnrealizedLoss	500000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-52338959	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-54169029	usd
CY2023	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0	usd
CY2022	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-52338959	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-54169029	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-52338959	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-54169029	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70580604	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70424819	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70580604	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70424819	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.77
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.77

Files In Submission

Name	View Source	Status
0001628280-24-009809-index-headers.html	Edgar Link	pending
0001628280-24-009809-index.html	Edgar Link	pending
0001628280-24-009809.txt	Edgar Link	pending
0001628280-24-009809-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ovid-20231231.htm	Edgar Link	pending
ovid-20231231.xsd	Edgar Link	pending
ovid-20231231_g1.jpg	Edgar Link	pending
ovid-20231231_g2.jpg	Edgar Link	pending
ovid-20231231_g3.jpg	Edgar Link	pending
ovid-20231231_g4.jpg	Edgar Link	pending
ovid-20231231_g5.jpg	Edgar Link	pending
ovid-20231231_def.xml	Edgar Link	unprocessable
ovid-20231231_g6.jpg	Edgar Link	pending
ovid-20231231_g7.jpg	Edgar Link	pending
ovid-ex42xdescriptionofc.htm	Edgar Link	pending
ovid-ex42xdescriptionofc001.jpg	Edgar Link	pending
ovid-ex42xdescriptionofc002.jpg	Edgar Link	pending
ovid-ex42xdescriptionofc003.jpg	Edgar Link	pending
ovid-ex42xdescriptionofc004.jpg	Edgar Link	pending
ovid-ex42xdescriptionofc005.jpg	Edgar Link	pending
ovid-royaltypurchaseagre.htm	Edgar Link	pending
ovid-royaltypurchaseagre001.jpg	Edgar Link	pending
ovid-royaltypurchaseagre002.jpg	Edgar Link	pending
ovid-royaltypurchaseagre003.jpg	Edgar Link	pending
ovid-royaltypurchaseagre004.jpg	Edgar Link	pending
ovid-royaltypurchaseagre005.jpg	Edgar Link	pending
ovid-royaltypurchaseagre006.jpg	Edgar Link	pending
ovid-royaltypurchaseagre007.jpg	Edgar Link	pending
ovid-royaltypurchaseagre008.jpg	Edgar Link	pending
ovid-royaltypurchaseagre009.jpg	Edgar Link	pending
ovid-royaltypurchaseagre010.jpg	Edgar Link	pending
ovid-royaltypurchaseagre011.jpg	Edgar Link	pending
ovid-royaltypurchaseagre012.jpg	Edgar Link	pending
ovid-royaltypurchaseagre013.jpg	Edgar Link	pending
ovid-royaltypurchaseagre014.jpg	Edgar Link	pending
ovid-royaltypurchaseagre015.jpg	Edgar Link	pending
ovid-royaltypurchaseagre016.jpg	Edgar Link	pending
ovid-royaltypurchaseagre017.jpg	Edgar Link	pending
ovid-royaltypurchaseagre018.jpg	Edgar Link	pending
ovid-royaltypurchaseagre019.jpg	Edgar Link	pending
ovid-royaltypurchaseagre020.jpg	Edgar Link	pending
ovid-royaltypurchaseagre021.jpg	Edgar Link	pending
ovid-royaltypurchaseagre022.jpg	Edgar Link	pending
ovid-royaltypurchaseagre023.jpg	Edgar Link	pending
ovid-royaltypurchaseagre024.jpg	Edgar Link	pending
ovid-royaltypurchaseagre025.jpg	Edgar Link	pending
ovid-royaltypurchaseagre026.jpg	Edgar Link	pending
ovid-royaltypurchaseagre027.jpg	Edgar Link	pending
ovid-royaltypurchaseagre028.jpg	Edgar Link	pending
ovid-royaltypurchaseagre029.jpg	Edgar Link	pending
ovid-royaltypurchaseagre030.jpg	Edgar Link	pending
ovid-royaltypurchaseagre031.jpg	Edgar Link	pending
ovid-royaltypurchaseagre032.jpg	Edgar Link	pending
ovid-royaltypurchaseagre033.jpg	Edgar Link	pending
ovid-royaltypurchaseagre034.jpg	Edgar Link	pending
ovid-royaltypurchaseagre035.jpg	Edgar Link	pending
ovid-20231231_htm.xml	Edgar Link	completed
ovid-royaltypurchaseagre036.jpg	Edgar Link	pending
ovid-royaltypurchaseagre037.jpg	Edgar Link	pending
ovid-royaltypurchaseagre038.jpg	Edgar Link	pending
ovid-royaltypurchaseagre039.jpg	Edgar Link	pending
ovid-royaltypurchaseagre040.jpg	Edgar Link	pending
ovid-royaltypurchaseagre041.jpg	Edgar Link	pending
ovid-royaltypurchaseagre042.jpg	Edgar Link	pending
ovid-royaltypurchaseagre043.jpg	Edgar Link	pending
ovid-royaltypurchaseagre044.jpg	Edgar Link	pending
ovid-royaltypurchaseagre045.jpg	Edgar Link	pending
ovid-royaltypurchaseagre046.jpg	Edgar Link	pending
ovid-royaltypurchaseagre047.jpg	Edgar Link	pending
ovid-royaltypurchaseagre048.jpg	Edgar Link	pending
ovid-royaltypurchaseagre049.jpg	Edgar Link	pending
ovid-royaltypurchaseagre050.jpg	Edgar Link	pending
ovid-royaltypurchaseagre051.jpg	Edgar Link	pending
ovid-royaltypurchaseagre052.jpg	Edgar Link	pending
ovid2023exhibit231.htm	Edgar Link	pending
ovid2023exhibit311.htm	Edgar Link	pending
ovid2023exhibit312.htm	Edgar Link	pending
ovid2023exhibit321.htm	Edgar Link	pending
ovidnon-employeedirector.htm	Edgar Link	pending
ovidnon-employeedirector001.jpg	Edgar Link	pending
ovidnon-employeedirector002.jpg	Edgar Link	pending
ovidtherapeuticsincincen.htm	Edgar Link	pending
ovidtherapeuticsincincen001.jpg	Edgar Link	pending
ovidtherapeuticsincincen002.jpg	Edgar Link	pending
ovidtherapeuticsincincen003.jpg	Edgar Link	pending
ovidtherapeuticsincincen004.jpg	Edgar Link	pending
ovidtherapeuticsincincen005.jpg	Edgar Link	pending
ovidtherapeuticsincincen006.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ovid-20231231_lab.xml	Edgar Link	unprocessable
ovid-20231231_pre.xml	Edgar Link	unprocessable
ovid-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OVID
Ovid Therapeutics Inc Stock $ovid

2024 Q1 Form 10-K Financial Statement

#000162828024009809 Filed on March 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OVID Ovid Therapeutics Inc Stock $ovid

2024 Q1 Form 10-K Financial Statement

#000162828024009809 Filed on March 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OVID
Ovid Therapeutics Inc Stock $ovid